In case of MS, therapeutic exosomes loaded with PROTACs against JAK/STAT signaling (eg, STAT3) would be beneficial since it can induce targeted degradation of STAT3 in microglia- or astrocytes-specific manner, improving the efficacy of drugs while reducing side-effects.70 Here, STAT3 is linked to myeloid sarcoma.